PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) today announced an approval of an additional indication for Opdivo (nivolumab) by the U.S. Food and Drug Administration.

Please see full Prescribing Information available at www.bms.com.

The company will provide additional details on the approval in a press release to follow.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews.

    CONTACT: Bristol-Myers Squibb Company
             Media:
             Carrie Fernandez, 609-419-5448
             carrie.fernandez@bms.com
             or
             Chrissy Trank, 609-252-3418
             christina.trank@bms.com
             or
             Investors:
             Ranya Dajani, 609-252-5330
             ranya.dajani@bms.com

    Source: Bristol-Myers Squibb Company